ITGA2B and Thrombocytopenia: Although the current study primarily targets thrombocytopenia induced by anti-CD41 antibody, LLLT-mediated enhancement of platelet production should be extended to ITP caused by other etiologies, such as anti-CD42b antibody or pathogenic T/B cell reactivity29, 36, as well as to those acquired thrombocytopenia that are not mediated by an immune mechanism including HIV, chemotherapy, and irradiation-induced thrombocytopenia18.